Synchronicity of Frequently Sampled, 24-H Concentrations of Circulating Leptin, Luteinizing Hormone, and Estradiol in Healthy Women

Total Page:16

File Type:pdf, Size:1020Kb

Synchronicity of Frequently Sampled, 24-H Concentrations of Circulating Leptin, Luteinizing Hormone, and Estradiol in Healthy Women Proc. Natl. Acad. Sci. USA Vol. 95, pp. 2541–2546, March 1998 Medical Sciences Synchronicity of frequently sampled, 24-h concentrations of circulating leptin, luteinizing hormone, and estradiol in healthy women JULIO LICINIO*†,ANDRE´ B. NEGRA˜O*, CHRISTOS MANTZOROS‡,VIRGINIA KAKLAMANI‡,MA-LI WONG*, PETER B. BONGIORNO*, ABEDA MULLA*, LAURA CEARNAL§,JOHANNES D. VELDHUIS¶,JEFFREY S. FLIER‡, i SAMUEL M. MCCANN , AND PHILIP W. GOLD* *Clinical Neuroendocrinology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892-1284; ‡Division of Endocrinology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215; §Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892; ¶Department of Internal Medicine and National Science Foundation Center for Biological Timing, University of Virginia Health Sciences Center, Charlottesville, VA 22908; and iPennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA 70808-4124 Contributed by Samuel M. McCann, December 29, 1997 ABSTRACT Leptin, an adipocyte hormone, is a trophic in uterine cross-sectional area, epithelial height, endometrial factor for the reproductive system; however, it is still unknown area, and glandular areas; in obyob males, 2 weeks of leptin whether there is a dynamic relation between fluctuations in treatment results in a rise in serum levels of follicle-stimulating circulating leptin and hypothalamic—pituitary–ovarian (HPO) hormone, as well as augmentation in the weights of the testes axis hormones. To test the hypothesis that fluctuations in plasma and seminal vesicles, associated with increases in the epithelial leptin concentrations are related to the levels of luteinizing height of the seminal vesicles (10). In humans, increases in hormone (LH) and estradiol, we sampled plasma from six plasma leptin concentrations seem to be associated with the healthy women every 7 min for 24 h during days 8–11 of the onset of puberty in boys. Mantzoros et al. (11) found that leptin menstrual cycle. Cross-correlation analysis throughout the 24-h levels rose by '50% before the onset of puberty in healthy boys cycle revealed a relation between release patterns of leptin and and decreased to baseline values after the initiation of puberty, LH, with a lag of 42–84 min but no significant cross-correlation remaining stable for extended periods; those changes occurred between LH and estradiol. The ultradian fluctuations in leptin despite constantly increasing body mass index (11). In persons levels showed pattern synchrony with those of both LH and with anorexia nervosa, low leptin levels may contribute to the estradiol as determined by cross-approximate entropy (cross- amenorrhea that is characteristic of that disorder (12–14). ApEn). At night, as leptin levels rose to their peak, the pulsatility Leptin acts not only in the hypothalamus (15), where it can profiles of LH changed significantly and became synchronous produce rapid synaptic modulatory effects (16) and increased with those of leptin. LH pulses were fewer, of longer duration, luteinizing hormone-releasing hormone release from medial basal higher amplitude, and larger area than during the day. More- hypothalamic explants (17), but it also has direct actions on the rat over, the synchronicity of LH and leptin occurred late at night, pituitary gland and ovary; in the pituitary, it stimulates luteinizing at which time estradiol and leptin also exhibited significantly hormone (LH) and follicle-stimulating hormone release (17), and stronger pattern coupling than during the day. We propose that in the ovary, it impairs the insulin-like growth factor I-mediated leptin may regulate the minute-to-minute oscillations in the augmentation of follicle-stimulating hormone-stimulated estradi- levels of LH and estradiol, and that the nocturnal rise in leptin ol-17b synthesis by granulosa cells (18). Thus, leptin can affect the may determine the change in nocturnal LH profile in the hypothalamic–pituitary–gonadal axis by direct actions in the hy- mid-to-late follicular phase that precedes ovulation. This may pothalamus, the pituitary gland, and the gonads. explain the disruption of hypothalamic—pituitary–ovarian Even though it is well established that leptin affects reproduc- function that is characteristic of states of low leptin release, such tive function, studies have not yet elucidated whether leptin is only as anorexia nervosa and cachexia. a necessary trophic factor for the reproductive system or whether the minute-to-minute dynamics of leptin concentrations are Leptin, the hormonal product of the OB gene (1), is a signal associated with hypothalamic–pituitary–ovarian (HPO) function. of nutritional status. High leptin levels in mice not only cause Our group and others have demonstrated that leptin concentra- weight loss, by suppressing food intake and increasing motor tions in human plasma have ultradian and circadian fluctuations activity, energy metabolism, oxygen consumption, and body (19–21). Because the hormones of the HPO axis exhibit striking temperature (2–4), but also stimulate reproduction. Admin- pulsatility, we designed a study to examine the hypothesis that istration of exogenous leptin to immature animals accelerates pulsatile release of leptin, LH, and estradiol exhibit pattern the onset of puberty (5, 6). In adult animals, leptin adminis- coupling or synchronicity by measuring plasma concentrations of tration corrects the sterility defect in homozygous obese the three hormones every 7 min throughout the 24 h. female mice (7) and corrects hypogonadism in mice starved for METHODS 2 days, without affecting body weight (8). In ad libitum-fed, but not in food-deprived, animals, leptin facilitates female sexual Clinical Research Protocol. Six healthy women were studied on behavior (9). Leptin treatment of obyob female mice for 2 days 8–11 of the menstrual cycle (mid-to-late follicular phase) weeks causes elevations of serum levels of LH, increases in after giving informed consent for a clinical research protocol ovarian and uterine weights and in total ovarian follicle approved by the National Institute of Mental Health Institutional number as well as primary and Graafian follicles, and increases Review Board. Partial results of leptin, but not LH or estradiol, The publication costs of this article were defrayed in part by page charge Abbreviations: LH, luteinizing hormone; ApEn, approximate entropy; HPO, hypothalamic-pituitary-ovarian; CV, coefficient of variation; payment. This article must therefore be hereby marked ‘‘advertisement’’ in PCOS, polycystic ovary syndrome. accordance with 18 U.S.C. §1734 solely to indicate this fact. †To whom reprint requests should be addressed at: Clinical Neuroendo- © 1998 by The National Academy of Sciences 0027-8424y98y952541-6$2.00y0 crinology Branch, NIMH, NIH, Building 10y2D46, 10 Center Drive, PNAS is available online at http:yywww.pnas.org. MSC 1284, Bethesda, MD 20892-1284. e-mail: [email protected]. 2541 Downloaded by guest on October 2, 2021 2542 Medical Sciences: Licinio et al. Proc. Natl. Acad. Sci. USA 95 (1998) concentrations have been reported (21). Subjects had an average higher leptin levels), we used CLUSTER (24), a computerized pulse age of 25.5 6 1.6 years and an average body mass index (calcu- analysis algorithm to identify statistically significant pulses in lated as the weight in kilograms divided by the square of the relation to measurement error in each hormone time series. The height in meters) of 21.6 6 1.1 kgym2. Women with history of use of this program has been described (21). Measurement error psychiatric or medical illness, obesity, smoking, or substance (within sample variance) for the 207 replicated samples in each abuse were excluded, as reported. For the 30-day period preced- series was modeled as a power function of sample concentration. ing each study, as well as during the study, no subject was taking Significantly increased or decreased hormone concentrations prescribed or over-the-counter medications, hormones, or di- (peak margins) were judged by pooled t statistics, which were etary supplements. applied to moving test nadirs and peak clusters that began with Subjects were acclimated to a research bed in the National the onset of the experimental series and traversed all points. We Institutes of Health Clinical Center for 48 h before the study. We identified the following mean properties of pulsatile hormone collected blood via an indwelling catheter that was inserted during concentrations: pulse frequency (number of significant peaksy24 the previous evening; samples were withdrawn every 7 min for h), interpeak interval (time separating consecutive peak maxi- 1442 min, yielding a total of 207 samples per subject, starting at ma), pulse duration in min, pulse height (maximal hormone 08:00 h. Clinical research protocol and diet are described in ref. concentration in a peak), pulse height as percentage increase over 21. Subjects were exposed to light from 07:00–23:00 h and were preceding baseline (100% corresponds to preceding baseline), studied in bed, in the dark from 23:00–07:00 h, during which time pulse area, and largest increase (increment) above pre-peak basal they slept. Sleep was monitored by the NightCap apparatus or nadir. (Healthdyne Technologies, Marietta, GA) (22, 23). To maintain Cross-Correlation Analysis. Cross-correlation was calculated their level of physical activity at a comparable baseline, on the
Recommended publications
  • Schizophrenia: Could It Be Prevented?
    SCHIZOPHRENIA : COULD IT BE PREVENTED ? A SATELLITE MEETING OF THE 2014 ANNUAL MEETING OF THE SOCIETY OF BIOLOGICAL PSYCHIATRY MAY 7, 2014 NEW YORK HILTON MIDTOWN TABLE OF CONTENTS WELCOME MESSAGE 3 ACKNOWLEDGMENTS 4 PROGRAM 5 INTRODUCTION – PROF . MICHEL CUENOD 6 SESSION 1: CHAIRS & SPEAKERS 7 SESSION 2: CHAIRS & SPEAKERS 14 SESSION 3: CHAIRS & SPEAKERS 19 2 WELCOME MESSAGE Early detection of psychotic disorders has recently become a focus for research and clinical development, leading to a major conceptual shift in psychiatry, and to the development of a preventive approach to psychiatric disorders. Based on emerging evidence that treatment delay has a negative impact on outcome, specialized programs to reduce the duration of untreated psychosis and develop specifically adapted treatments have been initiated worldwide. To this effect, it is essential to understand the underlying causes and mechanisms in order to identify key biomarkers profiles, and to develop novel therapeutic and preventive measures based on the etio-pathophysiology. Our Symposium brings together a panel of distinguished leaders in the field, who will present the state of the art of schizophrenia research with focus on pathophysiological mechanisms, genetic and environmental risk factors and their interaction during neurodevelopment. Dialogs between academia and industry on innovative solutions to therapeutic targets will contribute to shape the perspectives on preventive measures. Details regarding the course of the Symposium as well as our speakers and chairs are listed below. We trust that they will meet with your interest, and that we will have an opportunity to share experience, expand our networks, discuss collaborations and cultivate friendships. We thank you for joining us and look forward to a fruitful event.
    [Show full text]
  • Acute Systemic Inflammation Up-Regulates Secretory Sphingomyelinase in Vivo: a Possible Link Between Inflammatory Cytokines and Atherogenesis
    Acute systemic inflammation up-regulates secretory sphingomyelinase in vivo: A possible link between inflammatory cytokines and atherogenesis Ma-Li Wong*, Boxun Xie†, Nan Beatini†, Phan Phu‡, Sudhir Marathe†, Anthony Johns§, Philip W. Gold‡, Emmet Hirsch¶, Kevin Jon Williamsʈ, Julio Licinio*, and Ira Tabas†** *Department of Psychiatry and Biobehavioral Sciences, University of California, School of Medicine, Los Angeles, CA 90095-1761; Departments of †Medicine, Anatomy, and Cell Biology and ¶Obstetrics and Gynecology, Columbia University, New York, NY 10032; ‡Clinical Neuroendocrinology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892-1284; §Berlex Biosciences, Richmond, CA 94804; and ʈDorrance H. Hamilton Research Laboratories, Division of Endocrinology, Diabetes, and Metabolic Diseases, Thomas Jefferson University, Philadelphia, PA 19107 Edited by S. M. McCann, Pennington Biomedical Research Center, Baton Rouge, LA, and approved May 23, 2000 (received for review March 7, 2000) Inflammation plays a critical role in atherogenesis, yet the medi- sphingomyelinase (SMase) (20, 21). Ceramide generated from ators linking inflammation to specific atherogenic processes re- SMase activation has been reported to play roles in cytokine- main to be elucidated. One such mediator may be secretory mediated apoptosis, cellular differentiation, and cellular senes- sphingomyelinase (S-SMase), a product of the acid sphingomyeli- cence (20, 21), each of which may be important in the inflam- nase gene. The secretion of S-SMase by cultured endothelial cells matory response. Whereas studies in vitro have suggested roles is induced by inflammatory cytokines, and in vivo data have for several different mammalian SMase activities in various implicated S-SMase in subendothelial lipoprotein aggregation, ceramide signaling pathways (20, 21), a product of the acid macrophage foam cell formation, and possibly other atherogenic SMase (ASM) gene has been implicated in several specific processes.
    [Show full text]
  • Focus on Caspase 1, Inducible Nitric Oxide Synthase, and Interferon-Gamma
    Molecular Neurobiology https://doi.org/10.1007/s12035-018-1359-3 Neuroimmunomodulation in Major Depressive Disorder: Focus on Caspase 1, Inducible Nitric Oxide Synthase, and Interferon-Gamma Antonio Inserra1,2,3 & Claudio Alberto Mastronardi4,5 & Geraint Rogers6,7 & Julio Licinio8,9 & Ma-Li Wong1,2,9 Received: 29 April 2018 /Accepted: 19 September 2018 # The Author(s) 2018 Abstract Major depressive disorder (MDD) is one of the leading causes of disability worldwide, and its incidence is expected to increase. Despite tremendous efforts to understand its underlying biological mechanisms, MDD pathophysiology remains elusive and pharmacotherapy outcomes are still far from ideal. Low-grade chronic inflammation seems to play a key role in mediating the interface between psychological stress, depressive symptomatology, altered intestinal microbiology, and MDD onset. We review the available pre-clinical and clinical evidence of an involvement of pro-inflammatory pathways in the pathogenesis, treatment, and remission of MDD. We focus on caspase 1, inducible nitric oxide synthase, and interferon gamma, three inflammatory systems dysregulated in MDD. Treatment strategies aiming at targeting such pathways alone or in combination with classical therapies could prove valuable in MDD. Further studies are needed to assess the safety and efficacy of immune modulation in MDD and other psychiatric disorders with neuroinflammatory components. Keywords Major depressive disorder . MDD . Inflammation . Neuroinflammation . Caspase 1 . Inflammasome . T-helper 1 (Th1) . Interleukin 1 . Inducible nitric oxide synthase . Interferon gamma . Gut microbiome Introduction describe the elusive pathophysiology of MDD, including the monoamine hypothesis, the neurotrophic hypothesis, the gluta- Major depressive disorder (MDD) is a psychiatric disorder with mate hypothesis, the cytokine (or macrophage) hypothesis, and significant morbidity, mortality, disability, and economic bur- the microbiota-inflammasome hypothesis [8–13].
    [Show full text]
  • 2014 ADA Posters 1319-2206.Indd
    INTEGRATED PHYSIOLOGY—INSULINCATEGORY SECRETION IN VIVO 1738-P increase in tumor size and pulmonary metastasis is observed, compared Sustained Action of Ceramide on Insulin Signaling in Muscle Cells: to wild type mice. In this study, we aimed to determine the mechanisms Implication of the Double-Stranded RNA Activated Protein Kinase through which hyperinsulinemia and the canonical IR signaling pathway drive RIMA HAGE HASSAN, ISABELLE HAINAULT, AGNIESZKA BLACHNIO-ZABIELSKA, tumor growth and metastasis. 100,000 MVT-1 (c-myc/vegf overexpressing) RANA MAHFOUZ, OLIVIER BOURRON, PASCAL FERRÉ, FABIENNE FOUFELLE, ERIC cells were injected orthotopically into 8-10 week old MKR mice. MKR mice HAJDUCH, Paris, France, Białystok, Poland developed signifi cantly larger MVT-1 (353.29±44mm3) tumor volumes than Intramyocellular accumulation of fatty acid derivatives like ceramide plays control mice (183.21±47mm3), p<0.05 with more numerous pulmonary a crucial role in altering the insulin message. If short-term action of ceramide metastases. Western blot and immunofl uorescent staining of primary tumors inhibits the protein kinase B (PKB/Akt), long-term action of ceramide on insulin showed an increase in vimentin, an intermediate fi lament, typically expressed signaling is less documented. Short-term treatment of either the C2C12 cell in cells of mesenchymal origin, and c-myc, a known transcription factor. Both line or human myotubes with palmitate (ceramide precursor, 16h) or directly vimentin and c-myc are associated with cancer metastasis. To assess if insulin with ceramide (2h) induces a loss of the insulin signal through the inhibition and IR signaling directly affects the expression these markers, in vitro studies of PKB/Akt.
    [Show full text]
  • LEPTIN ENDOCRINE UPDATES Shlomo Melmed, M.D., Series Editor
    LEPTIN ENDOCRINE UPDATES Shlomo Melmed, M.D., Series Editor J.A. Fagin (ed.): Thyroid Cancer. 1998. ISBN: 0-7923-8326-5 J.S. Adams and B.P. Lukert (eds.): Osteoporosis: Genetics, Prevention and Treatment. 1998. ISBN: 0-7923-8366-4. B.-A. Bengtsson (ed.): Growth Hormone. 1999. ISBN: 0-7923-8478-4 C. Wang (ed.): Male Reproductive Function. 1999. ISBN: 0-7923-8520-9 B. Rapoport and S.M. McLachlan (eds.): Graves' Disease: Pathogenesis and Treatment. 2000. ISBN: 0-7923-7790-7. W. W. de Herder (ed.): Functional and Morphological Imaging of the Endocrine System. 2000. ISBN 0-7923-7923-9 H.G. Burger (ed.): Sex Hormone Replacement Therapy. 2001. ISBN 0-7923-7965-9 A. Giustina (ed.): Growth Hormone and the Heart. 2001. ISBN 0-7923-7212-3 W.L. Lowe, Jr. (ed.): Genetics of Diabetes Mellitus. 2001. ISBN 0-7923-7252-2 J.F. Habener and M.A. Hussain (eds.): Molecular Basis of Pancreas Development and Function. 2001. ISBN 0-7923-7271-9 N. Horseman (ed.): Prolactin. 2001. ISBN 0-7923-7290-5 M. Castro (ed.): Transgenic Models in Endocrinology. 2001 ISBN 0-7923-7344-8 R. Bahn (ed.): Thyroid Eye Disease. 2001. ISBN 0-7923-7380-4 M.D. Bronstein (ed.): Pituitary Tumors in Pregnancy ISBN 0-7923-7442-8 K. Sandberg and S.E. Mulroney (eds.): RNA Binding Proteins: New Concepts in Gene Regulation. 2001. ISBN 0-7923-7612-9 V. Goffin and P. A. Kelly (eds.): Hormone Signaling. 2002 ISBN 0-7923-7660-9 M. C. Sheppard and P. M. Stewart (eds.): Pituitary Disease. 2002 ISBN 1-4020-7122-1 N.
    [Show full text]
  • The Difference You Make
    THE DIFFERENCE YOU MAKE ANNUAL REPORT 2018–2019 TIME, TALENT, AND TREASURE This annual report affords me the chance to reflect on theT school’shis annual accomplishments report affords me over the chancethe past to yearreflect Center, and the Tata Innovation Center — that serve as withon thepride school’s and gratitude. accomplishments I am struck over by the what past we’ve year Johnson’s collective home. beenwith able pride to and achieve gratitude. together, I am stranduck so by grateful what we’ve Also in the vein of bringing people together, the forbeen the able community to achieve that together has built, and our so legacy grateful and for the Tata Innovation Center on Roosevelt Island now hosts continuescommunity to thatsupport has builtour ongoing our legacy growth. and continues numerous key Johnson programs: our Executive MBA/ to support our ongoing growth. MS in Healthcare Leadership, the Executive MBA Metro You are that community, and you are the reason NY, and, of course, the Cornell Tech MBA, as well as for Johnson’s success. supporting half-semester intensives and weekend As we all know, the people who make up courses that bring our Ithaca-based students to study Johnson are bright, driven, and accomplished, but what’s truly at the Cornell Tech campus. These significant developments help exceptional is their engagement and dedication. Members of the tie together different programs and student communities, allowing Johnson community have given so much of themselves to help students in executive MBA and residential MBA programs to work realize our success, and their ongoing dedication is inspiring.
    [Show full text]
  • The First International Conference on Translational Medicine
    Molecular Psychiatry (2010) 15, 878–879 & 2010 Macmillan Publishers Limited All rights reserved 1359-4184/10 www.nature.com/mp EDITORIAL The First International Conference on Translational Medicine Molecular Psychiatry (2010) 15, 878–879; doi:10.1038/ Table 1 First International Conference on Translational mp.2010.91 Medicine (The 13th Frank and Bobbie Fenner Conference), 1–4 November 2010, John Curtin School of Medical Research, As our mission to foster translational medicine ANU, Canberra, Australia continues to evolve, we have now conceptualized Participant leaders from the USA, Europe, China, and launched a new international conference to cover Singapore and Australia: the transition from discovery to healthcare and global Warwick Anderson, CEO, NHMRC, Australia health. The First International Conference on Transla- Juan Carlos Lopez, Chief Editor, Nature Medicine tional Medicine (the 13th Frank and Bobbie Fenner Anthony Hayward, Director, Clinical and Translational Conference) has a highly innovative mission of Program, NIH, USA bringing together into a global domain what have so Alan Schechter, Chief, Molecular Medicine, NIDDK, far been nationally focused efforts in translational NIH, USA medicine, such as the United States Clinical and Clay Johnston, Director, UCSF Clinical and Translational Translational Science Award (CTSA) mechanism and Science Institute the United Kingdom Academic Health Science Centre Anantha Shekhar, Director, Indiana Translational Institute, USA (AHSC) program. Initiatives from Ireland, which Dame Sally Davies, Director General of Research and created one academic health science center for the Development and Chief Scientific Adviser for the entire country, from China, Singapore and Australia Department of Health and NHS, London, UK will also be discussed and presented (see Table 1).
    [Show full text]
  • U.S. Department of Health and Human Services
    U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES SECRETARY'S ADVISORY COMMITTEE ON GENETICS, HEALTH, AND SOCIETY Eighth Meeting Friday, October 20, 2005 Brookside Room A/B Marriott Bethesda North Hotel and Montgomery County Conference Center 5701 Marinelli Road North Bethesda, Maryland IN ATTENDANCE: Acting Chair Cynthia E. Berry, J.D. Partner Powell Goldstein LLP 901 New York Avenue, N.W., 3rd Floor Washington, D.C. 20001 Members Sylvia Mann Au, M.S., C.G.C. State Genetics Coordinator Hawaii Department of Health Genetics Program 741 Sunset Avenue Honolulu, HI 96816 Chira Chen Staff Research Associate Comprehensive Cancer Center University of California, San Francisco 2340 Sutter Street, Suite N171 San Francisco, CA 94115 James P. Evans, M.D., Ph.D. Director of Clinical Genetics and the Bryson Program in Human Genetics University of North Carolina, Chapel Hill Medical Bioinformatics Research Building, Suite 4200 CB# 7264 103 Mason Farm Road Chapel Hill, NC 27599-7624 Kevin T. FitzGerald, S.J., Ph.D. Dr. David P. Lauler Chair in Catholic Health Care Ethics Research Associate Professor Department of Oncology Georgetown University Medical Center Building D, Suite 236 4000 Reservoir Road, N.W. Washington, D.C. 20057 IN ATTENDANCE: Julio Licinio, M.D. Professor of Psychiatry and Medicine/Endocrinology Neuropsychiatric Institute David Geffen School of Medicine at UCLA University of California, Los Angeles Gonda Center, Room 3357A 695 Charles Young Drive South Los Angeles, CA 90095-1761 Agnes Masny, R.N., M.P.H., M.S.N. Adjunct Assistant Professor of Nursing Temple University College of Allied Health Professionals Research Assistant and Nurse Practitioner Family Risk Assessment Program Fox Chase Cancer Center Prevention Pavilion 7701 Burholme Avenue Philadelphia, PA 19111 Joseph Telfair, Dr.P.H., M.S.W., M.P.H.
    [Show full text]
  • Acetyl-L-Carnitine Deficiency in Patients with Major Depressive Disorder
    Acetyl-L-carnitine deficiency in patients with major SEE COMMENTARY depressive disorder Carla Nascaa,1, Benedetta Bigioa,b, Francis S. Leec,d, Sarah P. Younge,f, Marin M. Kautzg, Ashly Albrightd, James Beasleyf, David S. Millingtone,f, Aleksander A. Mathéh, James H. Kocsisd, James W. Murroughg, Bruce S. McEwena,1, and Natalie Rasgona,i aHarold and Margaret Milliken Hatch Laboratory of Neuroendocrinology, The Rockefeller University, New York, NY 10065; bBiostatistics and Experimental Research Design, Center for Clinical and Translational Science, The Rockefeller University, New York, NY 10065; cSackler Institute for Developmental Psychobiology, Weill Cornell Medical College, New York, NY 10065; dDepartment of Psychiatry, Weill Cornell Medical College, New York, NY 10065; eDivision of Medical Genetics, Department of Pediatrics, Duke University School of Medicine, Durham, NC 27710; fBiochemical Genetics Laboratory, Duke University Health System, Durham, NC 27710; gMood and Anxiety Disorders Program, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY 10029; hDepartment of Clinical Neuroscience, Karolinska Institutet, SE-171 77 Stockholm, Sweden; and iCenter for Neuroscience in Women’s Health, Stanford University, Palo Alto, CA 94305 Contributed by Bruce S. McEwen, June 15, 2018 (sent for review February 2, 2018; reviewed by Julio Licinio, Robert M. Post, and Charles L. Raison) The lack of biomarkers to identify target populations greatly limits neurotrophic factor (BDNF) and a critical regulator of synaptic the promise of precision medicine for major depressive disorder glutamate release, the metabotropic glutamate receptor of class-2, (MDD), a primary cause of ill health and disability. The endoge- mGlu2 (10, 16–18). In several animal models, LAC supplementa- nously produced molecule acetyl-L-carnitine (LAC) is critical for hip- tion has been shown to ameliorate glutamatergic dysfunction and pocampal function and several behavioral domains.
    [Show full text]
  • Annual Meeting
    2018 Annual Meeting Preliminary Program and Registration Information Join the conversation: #APAAM18 psychiatry.org/annualmeeting ANNUAL MEETING May 5-9, 2018 • New York City 2 Table of Contents Building Well-Being Through Innovation 3 Frequently Asked Questions 39 Schedule-at-a-Glance 5 Getting to New York 45 General Information 7 Hotel Reservation Information 50 Program Format Descriptions 11 Hotel Descriptions 51 Learning Labs 14 Hotel Listings and Amenities 55 Master Course Listings 18 Hotel Map 57 Course Listings 20 Shuttle Bus Routes 58 Scientific Program Lecturers 35 Registration Information 59 APA Administration Meetings and Conventions Scientific Program Committee Consultants CEO and Medical Cathy L. Nash, CMP Linda L. M. Worley, M.D. Josepha Cheong, M.D. Director's Office Director Chairperson David F. Gitlin, M.D. Jacqueline Feldman, M.D. Saul Levin, M.D., M.P.A. Vernetta Copeland Margo Lauterbach, M.D. Iqbal Ahmed, M.D. Chief Executive Officer and Associate Director Susan V. McLeer, M.D. Medical Director Vice-Chairpersons Stephanie Dumey, CMP Sarah Oreck, M.D., M.S. Associate Director Division of Education APA President Eric R. Williams, M.D. Tristan Gorrindo, M.D. Chantalle Hinton Anita Everett, M.D. Corresponding Members Deputy Medical Director Associate Director Members Alvaro Camacho, M.D. Director, Education Division Traci Williams Lara J. Cox, M.D. J. Raymond DePaulo, M.D. Nina Taylor, M.A. Senior Meeting Planner Nancy Diazgranados, M.D. Maria I. Lapid, M.D. Deputy Director, Education Jamie Woodside, CEM Anna L. Dickerman, M.D. Division Exhibits & Meetings Manager Julio Licinio, M.D. Donald C. Goff, M.D.
    [Show full text]
  • Mind and Brain Theme Student Opportunities
    Mind and Brain Theme Student Opportunities Project 1: Chronic fatigue syndrome: Leptin, interleukin 6 and clinical symptoms Supervisors: Professor Julio Licinio, Dr Michael Musker Student: Honours Chronic fatigue syndrome (CFS) is characterised by a constellation of symptoms in previously healthy and active individuals. Because of these symptoms, quality of life of persons with CFS can be extremely compromised. While the search for a clear-cut cause remains elusive, we believe that we can make a major contribution to patient’s quality of life by elucidating the biological basis of their clinical symptoms. If the proximal biology underlying the disabling symptoms of CFS is elucidated, we will be able to target treatments aimed at symptomatic improvement. This project will involve assisting the research team in setting up human research study, interviewing participants, sampling and storage processes for bloods, collecting data from human participants in a mental health context, data collation and analysis. Mind & Brain: Laboratory Research The laboratory research group addresses the mechanisms of mind & brain disorders utilising molecular techniques and models in a laboratory environment. Project 2: The role of stress in cancer initiation and progression Supervisors: Professor Julio Licinio, Dr Martin Lewis, Mr Rhys Fogarty Student: Honours There is growing evidence that chronic psychosocial stress contributes to cancer initiation and progression, however the molecular mechanisms underlying this phenomenon are poorly understood. Chronic exposure of cells to hormones released during stress may activate pro- malignant pathways that increase the cell’s susceptibility to carcinogens and enhance malignant characteristics. The aim of this work is to use an in vitro model of chronic stress involving long-term exposure of cancer and normal cell lines to stress hormones.
    [Show full text]
  • Depression and Obesity Treatments Are Life Saving
    LETTERS TO THE EDITOR Depression and obesity treatments are life saving To the editor—I was disappointed to read United States3. When causes of death are University of California, Los Angeles in your September 2002 issue a classifica- examined by age group, the importance Los Angeles, California, USA tion of antidepressants and antiobesity of suicide as a cause of death is self-evi- Email: [email protected] drugs as “lifestyle drugs”1. Depression is dent (Table 1)3. Moreover, depression is not a lifestyle; it is a severe medical disor- an independent risk factor for heart dis- We reply—We certainly agree that depres- der that has been recognized as such ease, which is the leading cause of mor- sion and obesity are potentially life-threat- 2 since antiquity . Melancholia (black bile tality in the US. In this context, ening conditions, and regret the in Greek) is a subtype of depression that antidepressant treatment is not a characterization of these in our news story was named by Hippocrates 2,500 years lifestyle option, it is a life-saving neces- as mere “lifestyles”. However, we stand by ago. It is the only disease category to sity. the main part of the piece, which focused have survived in its original name from Obesity is also a key contributor to not only on these conditions, but on other the Hippocratic classification of disease morbidity and mortality and can have a afflictions currently the focus of pharma- 2 based on the four humors . Moreover, profound negative impact on health and ceutical development, including hair loss, people die of depression, and do so in life expectancy.
    [Show full text]